Saturday, September 9, 2017
Alzheimer's: Treating with a daily pill in the future? VIDEO
Who's most-at-risk for developing Alzheimer's disease?
The Alzheimer's Association reveals new data about who's most-at-risk for the disease
A Boston-based startup called Lyndra that specializes in developing long-acting drug delivery has announced an exclusive partnership with drug giant Allergan (AGN) to develop a once-weekly drug to fight Alzheimer’s disease.
The deal, which consists of an upfront payment of $15 million to Lyndra and up to $90 million in development and regulatory milestones, marks the largest deal to date in an effort to find a way to treat the more than 50 million people who are living with Alzheimer’s or dementia worldwide, according to the Alzheimer’s Association.
The partnership also follows Lyndra’s Series A round of $23 million announced earlier this spring.
Lyndra’s CEO Amy Schulman said in a statement that creating a daily pill instead having patients take multiple pills will ease the burden of medication compliance and simple the day-to-day challenges of chronic conditions.
Story Source: The above story is based on materials provided by FOXBUSINESS
Note: Materials may be edited for content and length
Click here to see more